Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. Cunningham D, Pyrhonen S, James RD, et al.: Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352:1413–1418.
2. Rougier P, Man Cutsem E, Bajetta E, et al.: Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998, 352:1407–1412.
3. Saltz LB, Locker PK, Pirotta N, et al.: Weekly irinotecan (CPT-11), leucovorin, and fluorouracil is superior to daily x 5 leucovorin + 5-FU in patients with previously untreated metastatic colorectal cancer [abstract]. Proc ASCO 1999, 18:233.
4. Douillard JY, Cunningham D, Roth AD, et al.: A randomized phase III trial comparing irinotecan + 5-FU + folinic acid to the same schedule of 5-FU+ folinic acid in patients with metastatic colorectal cancer as front line chemotherapy. Lancet 2000, 355:1041–1047.
5. Rixe O, Ortuzar W, Alvarez M, et al.: Oxaliplatin, tetraplatin, cesplatin, and carboplatin: spectrum of activity in drugresistant cell lines and in the cell lines of the National Cancer Institute’s Anticancer Drug Screen panel. Biochem Pharmacol 1996, 52:1855–1865.
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献